100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AI181292
Award Date
2/26/24
Completion Date
1/31/27
Dollars Obligated
$1.5M
Overview
Activity
6
Transactions
6
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Abvacc, Inc. (K5MSGRFGVVZ9)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Update #1
Update #2
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST
Posted 2/26/24
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST - THERE IS AN OUTBREAK OF MARBURG VIRUS DISEASE (MVD), RELATIVE OF EBOLA VIRUS, CURRENTLY ONGOING IN EQUATORIAL GUINEA AND TANZANIA. THERE HAVE BEEN MULTIPLE, DEADLY OUTBREAKS OF MVD IN THE PAST WITH ~88% LETHALITY. THERE ARE CURRENTLY NO APPROVED VACCINES OR THERAPEUTICS FOR MVD AND VERY FEW IN CLINICAL DEVELOPMENT. IN THIS PROPOSAL, WE HAVE RATIONALLY DESIGNED AN IMMUNOGEN BASED ON MARV GLYCOPROTEIN (GP) BY EXCLUDING DOMAINS KNOWN TO TRIGGER NON-NEUTRALIZING ANTIBODIES ALLOWING EXPOSURE OF KEY NEUTRALIZING EPITOPES CAPABLE OF GENERATING A STRONG IMMUNE RESPONSE. COMBINED WITH A NOVEL TLR7/8 AGONIST ADJUVANT, ALHYDROXYQUIM- II (AHQ-II), THAT HAS SHOWN EXCELLENT SAFETY AND ADJUVANT ACTIVITY IN MILLIONS OF PEOPLE DURING COVID-19 PANDEMIC, OUR RATIONALLY DESIGNED MARV VACCINE INDUCES BROADLY NEUTRALIZING ANTIBODIES AGAINST ISOLATES ANGOLA, CI67, AND MUSOKE STRAINS OF MARV AS WELL AS THE PHYLOGENETICALLY MORE DISTANT RAVV. MICE IMMUNIZED WITH THIS MARV VACCINE WITH TWO OR THREE DOSES COMPARED TO UNADJUVANTED ANTIGEN SHOWED ROBUST ANTIGEN-SPECIFIC BINDING AND NEUTRALIZING TITERS AGAINST ALL FOUR MARV STRAINS DEMONSTRATED BY ELISA AND PSEUDOVIRUS NEUTRALIZATION ASSAYS. IN THE GUINEA PIG MODEL OF MARV INFECTION WHICH SHOWS ALL HALLMARKS OF FILOVIRUS DISEASE THE VACCINE PROVIDED 100% PROTECTION AGAINST LETHAL CHALLENGE WITH NO DETECTABLE VIREMIA, SUGGESTING THAT THE VACCINE IS LIKELY INDUCING STERILIZING IMMUNITY. IN SUMMARY, THIS SUBUNIT VACCINE REPRESENTS A NOVEL, HIGHLY EFFICACIOUS, AND SAFE CANDIDATE FOR PROTECTION AGAINST MVD. HERE, WE PROPOSE THREE SPECIFIC AIMS TO FURTHER DEVELOP THIS RATIONALLY DESIGNED IMMUNOGEN: AIM1: TO PRODUCE AND GENERATE A POOLED STABLE CELL LINE FOR THE MARV SUBUNIT ANTIGEN WITH A CGMP-COMPLIANT TAG AND DEMONSTRATE BIOCHEMICAL AND IMMUNOGENIC PROPERTIES COMPARABLE TO THE STREPTAVIDIN-TAGGED MARV MATERIAL USED IN PRELIMINARY STUDIES; AIM 2: TO DETERMINE OPTIMAL EFFECTIVE DOSE AND REGIMEN FOR MAXIMUM PROTECTION IN BSL-4 GUINEA PIG MARV MODEL; AIM 3: TO DEMONSTRATE IMMUNOGENICITY IN THE FILOVIRUS GOLD STANDARD NON-HUMAN PRIMATE MODEL. UPON SUCCESSFUL COMPLETION OF THIS PHASE I PROJECT WE ANTICIPATE A PHASE II FOCUSED ON NHP EFFICACY STUDIES AND ADVANCED DEVELOPMENT ACTIVITIES.
$0
11/13/25
Not listed
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST - THERE IS AN OUTBREAK OF MARBURG VIRUS DISEASE (MVD), RELATIVE OF EBOLA VIRUS, CURRENTLY ONGOING IN EQUATORIAL GUINEA AND TANZANIA. THERE HAVE BEEN MULTIPLE, DEADLY OUTBREAKS OF MVD IN THE PAST WITH ~88% LETHALITY. THERE ARE CURRENTLY NO APPROVED VACCINES OR THERAPEUTICS FOR MVD AND VERY FEW IN CLINICAL DEVELOPMENT. IN THIS PROPOSAL, WE HAVE RATIONALLY DESIGNED AN IMMUNOGEN BASED ON MARV GLYCOPROTEIN (GP) BY EXCLUDING DOMAINS KNOWN TO TRIGGER NON-NEUTRALIZING ANTIBODIES ALLOWING EXPOSURE OF KEY NEUTRALIZING EPITOPES CAPABLE OF GENERATING A STRONG IMMUNE RESPONSE. COMBINED WITH A NOVEL TLR7/8 AGONIST ADJUVANT, ALHYDROXYQUIM- II (AHQ-II), THAT HAS SHOWN EXCELLENT SAFETY AND ADJUVANT ACTIVITY IN MILLIONS OF PEOPLE DURING COVID-19 PANDEMIC, OUR RATIONALLY DESIGNED MARV VACCINE INDUCES BROADLY NEUTRALIZING ANTIBODIES AGAINST ISOLATES ANGOLA, CI67, AND MUSOKE STRAINS OF MARV AS WELL AS THE PHYLOGENETICALLY MORE DISTANT RAVV. MICE IMMUNIZED WITH THIS MARV VACCINE WITH TWO OR THREE DOSES COMPARED TO UNADJUVANTED ANTIGEN SHOWED ROBUST ANTIGEN-SPECIFIC BINDING AND NEUTRALIZING TITERS AGAINST ALL FOUR MARV STRAINS DEMONSTRATED BY ELISA AND PSEUDOVIRUS NEUTRALIZATION ASSAYS. IN THE GUINEA PIG MODEL OF MARV INFECTION WHICH SHOWS ALL HALLMARKS OF FILOVIRUS DISEASE THE VACCINE PROVIDED 100% PROTECTION AGAINST LETHAL CHALLENGE WITH NO DETECTABLE VIREMIA, SUGGESTING THAT THE VACCINE IS LIKELY INDUCING STERILIZING IMMUNITY. IN SUMMARY, THIS SUBUNIT VACCINE REPRESENTS A NOVEL, HIGHLY EFFICACIOUS, AND SAFE CANDIDATE FOR PROTECTION AGAINST MVD. HERE, WE PROPOSE THREE SPECIFIC AIMS TO FURTHER DEVELOP THIS RATIONALLY DESIGNED IMMUNOGEN: AIM1: TO PRODUCE AND GENERATE A POOLED STABLE CELL LINE FOR THE MARV SUBUNIT ANTIGEN WITH A CGMP-COMPLIANT TAG AND DEMONSTRATE BIOCHEMICAL AND IMMUNOGENIC PROPERTIES COMPARABLE TO THE STREPTAVIDIN-TAGGED MARV MATERIAL USED IN PRELIMINARY STUDIES; AIM 2: TO DETERMINE OPTIMAL EFFECTIVE DOSE AND REGIMEN FOR MAXIMUM PROTECTION IN BSL-4 GUINEA PIG MARV MODEL; AIM 3: TO DEMONSTRATE IMMUNOGENICITY IN THE FILOVIRUS GOLD STANDARD NON-HUMAN PRIMATE MODEL. UPON SUCCESSFUL COMPLETION OF THIS PHASE I PROJECT WE ANTICIPATE A PHASE II FOCUSED ON NHP EFFICACY STUDIES AND ADVANCED DEVELOPMENT ACTIVITIES.
$297.1k
1/17/25
Not listed
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST - THERE IS AN OUTBREAK OF MARBURG VIRUS DISEASE (MVD), RELATIVE OF EBOLA VIRUS, CURRENTLY ONGOING IN EQUATORIAL GUINEA AND TANZANIA. THERE HAVE BEEN MULTIPLE, DEADLY OUTBREAKS OF MVD IN THE PAST WITH ~88% LETHALITY. THERE ARE CURRENTLY NO APPROVED VACCINES OR THERAPEUTICS FOR MVD AND VERY FEW IN CLINICAL DEVELOPMENT. IN THIS PROPOSAL, WE HAVE RATIONALLY DESIGNED AN IMMUNOGEN BASED ON MARV GLYCOPROTEIN (GP) BY EXCLUDING DOMAINS KNOWN TO TRIGGER NON-NEUTRALIZING ANTIBODIES ALLOWING EXPOSURE OF KEY NEUTRALIZING EPITOPES CAPABLE OF GENERATING A STRONG IMMUNE RESPONSE. COMBINED WITH A NOVEL TLR7/8 AGONIST ADJUVANT, ALHYDROXYQUIM- II (AHQ-II), THAT HAS SHOWN EXCELLENT SAFETY AND ADJUVANT ACTIVITY IN MILLIONS OF PEOPLE DURING COVID-19 PANDEMIC, OUR RATIONALLY DESIGNED MARV VACCINE INDUCES BROADLY NEUTRALIZING ANTIBODIES AGAINST ISOLATES ANGOLA, CI67, AND MUSOKE STRAINS OF MARV AS WELL AS THE PHYLOGENETICALLY MORE DISTANT RAVV. MICE IMMUNIZED WITH THIS MARV VACCINE WITH TWO OR THREE DOSES COMPARED TO UNADJUVANTED ANTIGEN SHOWED ROBUST ANTIGEN-SPECIFIC BINDING AND NEUTRALIZING TITERS AGAINST ALL FOUR MARV STRAINS DEMONSTRATED BY ELISA AND PSEUDOVIRUS NEUTRALIZATION ASSAYS. IN THE GUINEA PIG MODEL OF MARV INFECTION WHICH SHOWS ALL HALLMARKS OF FILOVIRUS DISEASE THE VACCINE PROVIDED 100% PROTECTION AGAINST LETHAL CHALLENGE WITH NO DETECTABLE VIREMIA, SUGGESTING THAT THE VACCINE IS LIKELY INDUCING STERILIZING IMMUNITY. IN SUMMARY, THIS SUBUNIT VACCINE REPRESENTS A NOVEL, HIGHLY EFFICACIOUS, AND SAFE CANDIDATE FOR PROTECTION AGAINST MVD. HERE, WE PROPOSE THREE SPECIFIC AIMS TO FURTHER DEVELOP THIS RATIONALLY DESIGNED IMMUNOGEN: AIM1: TO PRODUCE AND GENERATE A POOLED STABLE CELL LINE FOR THE MARV SUBUNIT ANTIGEN WITH A CGMP-COMPLIANT TAG AND DEMONSTRATE BIOCHEMICAL AND IMMUNOGENIC PROPERTIES COMPARABLE TO THE STREPTAVIDIN-TAGGED MARV MATERIAL USED IN PRELIMINARY STUDIES; AIM 2: TO DETERMINE OPTIMAL EFFECTIVE DOSE AND REGIMEN FOR MAXIMUM PROTECTION IN BSL-4 GUINEA PIG MARV MODEL; AIM 3: TO DEMONSTRATE IMMUNOGENICITY IN THE FILOVIRUS GOLD STANDARD NON-HUMAN PRIMATE MODEL. UPON SUCCESSFUL COMPLETION OF THIS PHASE I PROJECT WE ANTICIPATE A PHASE II FOCUSED ON NHP EFFICACY STUDIES AND ADVANCED DEVELOPMENT ACTIVITIES.
$297.1k
1/17/25
Not listed
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST - THERE IS AN OUTBREAK OF MARBURG VIRUS DISEASE (MVD), RELATIVE OF EBOLA VIRUS, CURRENTLY ONGOING IN EQUATORIAL GUINEA AND TANZANIA. THERE HAVE BEEN MULTIPLE, DEADLY OUTBREAKS OF MVD IN THE PAST WITH ~88% LETHALITY. THERE ARE CURRENTLY NO APPROVED VACCINES OR THERAPEUTICS FOR MVD AND VERY FEW IN CLINICAL DEVELOPMENT. IN THIS PROPOSAL, WE HAVE RATIONALLY DESIGNED AN IMMUNOGEN BASED ON MARV GLYCOPROTEIN (GP) BY EXCLUDING DOMAINS KNOWN TO TRIGGER NON-NEUTRALIZING ANTIBODIES ALLOWING EXPOSURE OF KEY NEUTRALIZING EPITOPES CAPABLE OF GENERATING A STRONG IMMUNE RESPONSE. COMBINED WITH A NOVEL TLR7/8 AGONIST ADJUVANT, ALHYDROXYQUIM- II (AHQ-II), THAT HAS SHOWN EXCELLENT SAFETY AND ADJUVANT ACTIVITY IN MILLIONS OF PEOPLE DURING COVID-19 PANDEMIC, OUR RATIONALLY DESIGNED MARV VACCINE INDUCES BROADLY NEUTRALIZING ANTIBODIES AGAINST ISOLATES ANGOLA, CI67, AND MUSOKE STRAINS OF MARV AS WELL AS THE PHYLOGENETICALLY MORE DISTANT RAVV. MICE IMMUNIZED WITH THIS MARV VACCINE WITH TWO OR THREE DOSES COMPARED TO UNADJUVANTED ANTIGEN SHOWED ROBUST ANTIGEN-SPECIFIC BINDING AND NEUTRALIZING TITERS AGAINST ALL FOUR MARV STRAINS DEMONSTRATED BY ELISA AND PSEUDOVIRUS NEUTRALIZATION ASSAYS. IN THE GUINEA PIG MODEL OF MARV INFECTION WHICH SHOWS ALL HALLMARKS OF FILOVIRUS DISEASE THE VACCINE PROVIDED 100% PROTECTION AGAINST LETHAL CHALLENGE WITH NO DETECTABLE VIREMIA, SUGGESTING THAT THE VACCINE IS LIKELY INDUCING STERILIZING IMMUNITY. IN SUMMARY, THIS SUBUNIT VACCINE REPRESENTS A NOVEL, HIGHLY EFFICACIOUS, AND SAFE CANDIDATE FOR PROTECTION AGAINST MVD. HERE, WE PROPOSE THREE SPECIFIC AIMS TO FURTHER DEVELOP THIS RATIONALLY DESIGNED IMMUNOGEN: AIM1: TO PRODUCE AND GENERATE A POOLED STABLE CELL LINE FOR THE MARV SUBUNIT ANTIGEN WITH A CGMP-COMPLIANT TAG AND DEMONSTRATE BIOCHEMICAL AND IMMUNOGENIC PROPERTIES COMPARABLE TO THE STREPTAVIDIN-TAGGED MARV MATERIAL USED IN PRELIMINARY STUDIES; AIM 2: TO DETERMINE OPTIMAL EFFECTIVE DOSE AND REGIMEN FOR MAXIMUM PROTECTION IN BSL-4 GUINEA PIG MARV MODEL; AIM 3: TO DEMONSTRATE IMMUNOGENICITY IN THE FILOVIRUS GOLD STANDARD NON-HUMAN PRIMATE MODEL. UPON SUCCESSFUL COMPLETION OF THIS PHASE I PROJECT WE ANTICIPATE A PHASE II FOCUSED ON NHP EFFICACY STUDIES AND ADVANCED DEVELOPMENT ACTIVITIES.
$299.5k
2/26/24
Not listed
DEVELOPMENT OF A MARBURGVIRUS SUBUNIT VACCINEADJUVANTED WITH A NOVEL TLR7/TLR8 AGONIST - THERE IS AN OUTBREAK OF MARBURG VIRUS DISEASE (MVD), RELATIVE OF EBOLA VIRUS, CURRENTLY ONGOING IN EQUATORIAL GUINEA AND TANZANIA. THERE HAVE BEEN MULTIPLE, DEADLY OUTBREAKS OF MVD IN THE PAST WITH ~88% LETHALITY. THERE ARE CURRENTLY NO APPROVED VACCINES OR THERAPEUTICS FOR MVD AND VERY FEW IN CLINICAL DEVELOPMENT. IN THIS PROPOSAL, WE HAVE RATIONALLY DESIGNED AN IMMUNOGEN BASED ON MARV GLYCOPROTEIN (GP) BY EXCLUDING DOMAINS KNOWN TO TRIGGER NON-NEUTRALIZING ANTIBODIES ALLOWING EXPOSURE OF KEY NEUTRALIZING EPITOPES CAPABLE OF GENERATING A STRONG IMMUNE RESPONSE. COMBINED WITH A NOVEL TLR7/8 AGONIST ADJUVANT, ALHYDROXYQUIM- II (AHQ-II), THAT HAS SHOWN EXCELLENT SAFETY AND ADJUVANT ACTIVITY IN MILLIONS OF PEOPLE DURING COVID-19 PANDEMIC, OUR RATIONALLY DESIGNED MARV VACCINE INDUCES BROADLY NEUTRALIZING ANTIBODIES AGAINST ISOLATES ANGOLA, CI67, AND MUSOKE STRAINS OF MARV AS WELL AS THE PHYLOGENETICALLY MORE DISTANT RAVV. MICE IMMUNIZED WITH THIS MARV VACCINE WITH TWO OR THREE DOSES COMPARED TO UNADJUVANTED ANTIGEN SHOWED ROBUST ANTIGEN-SPECIFIC BINDING AND NEUTRALIZING TITERS AGAINST ALL FOUR MARV STRAINS DEMONSTRATED BY ELISA AND PSEUDOVIRUS NEUTRALIZATION ASSAYS. IN THE GUINEA PIG MODEL OF MARV INFECTION WHICH SHOWS ALL HALLMARKS OF FILOVIRUS DISEASE THE VACCINE PROVIDED 100% PROTECTION AGAINST LETHAL CHALLENGE WITH NO DETECTABLE VIREMIA, SUGGESTING THAT THE VACCINE IS LIKELY INDUCING STERILIZING IMMUNITY. IN SUMMARY, THIS SUBUNIT VACCINE REPRESENTS A NOVEL, HIGHLY EFFICACIOUS, AND SAFE CANDIDATE FOR PROTECTION AGAINST MVD. HERE, WE PROPOSE THREE SPECIFIC AIMS TO FURTHER DEVELOP THIS RATIONALLY DESIGNED IMMUNOGEN: AIM1: TO PRODUCE AND GENERATE A POOLED STABLE CELL LINE FOR THE MARV SUBUNIT ANTIGEN WITH A CGMP-COMPLIANT TAG AND DEMONSTRATE BIOCHEMICAL AND IMMUNOGENIC PROPERTIES COMPARABLE TO THE STREPTAVIDIN-TAGGED MARV MATERIAL USED IN PRELIMINARY STUDIES; AIM 2: TO DETERMINE OPTIMAL EFFECTIVE DOSE AND REGIMEN FOR MAXIMUM PROTECTION IN BSL-4 GUINEA PIG MARV MODEL; AIM 3: TO DEMONSTRATE IMMUNOGENICITY IN THE FILOVIRUS GOLD STANDARD NON-HUMAN PRIMATE MODEL. UPON SUCCESSFUL COMPLETION OF THIS PHASE I PROJECT WE ANTICIPATE A PHASE II FOCUSED ON NHP EFFICACY STUDIES AND ADVANCED DEVELOPMENT ACTIVITIES.
$299.5k
2/26/24